

1 **Virus-derived DNA forms mediate the persistent infection of tick cells by**  
2 **Hazara virus and Crimean-Congo hemorrhagic fever virus**

3 Maria Vittoria Salvati<sup>a</sup>, Claudio Salaris<sup>a</sup>, Vanessa Monteil<sup>b,c</sup>, Claudia Del Vecchio<sup>a</sup>, Giorgio Palù<sup>a</sup>,  
4 Cristina Parolin<sup>a</sup>, Arianna Calistri<sup>a</sup>, Lesley Bell-Sakyi<sup>d</sup>, Ali Mirazimi<sup>b,c,e\*</sup>, Cristiano Salata<sup>a\*</sup>

5 <sup>a</sup>Department of Molecular Medicine, University of Padova, Via Gabelli, 63, IT-35121 Padova, Italy

6 <sup>b</sup>Department of Microbiology, Public Health Agency of Sweden, Nobels Väg 18, SE-171 82 Solna,  
7 Sweden

8 <sup>c</sup>Department of Laboratory Medicine, Karolinska University Hospital and KI, SE-14186 Huddinge  
9 Stockholm, Sweden

10 <sup>d</sup>Department of Infection Biology and Microbiomes, Institute of Infection, Veterinary and  
11 Ecological Sciences, University of Liverpool, Liverpool Science Park IC2, 146 Brownlow Hill,  
12 Liverpool L3 5RF, United Kingdom.

13 <sup>e</sup>National Veterinary Institute, SE-756 51, Uppsala, Sweden

14 \*Corresponding authors:

15 Cristiano Salata, Department of Molecular Medicine, University of Padova, Via Gabelli, 63, IT-  
16 35121 Padova, Italy. Phone: +390498272364; e-mail: [cristiano.salata@unipd.it](mailto:cristiano.salata@unipd.it)

17 Ali Mirazimi, Department of Laboratory Medicine, Karolinska University Hospital and KI, SE-  
18 14186 Huddinge Stockholm, Sweden. e-mail: [ali.mirazimi@ki.se](mailto:ali.mirazimi@ki.se)

19 **Running title:** role of vDNAs in tick cell infection

20 **Abstract:** 230 words

21 **Text:** 4963 words

22 **Figures and tables:** 8

23

24

25

26 **ABSTRACT**

27 Crimean-Congo hemorrhagic fever (CCHF) is a severe disease of humans caused by CCHF virus  
28 (CCHFV), a biosafety level (BSL)-4 pathogen. Ticks of the genus *Hyalomma* are the viral reservoir  
29 and they represent the main vector transmitting the virus to its hosts during blood feeding. We have  
30 previously shown that CCHFV can persistently infect *Hyalomma*-derived tick cell lines. However,  
31 the mechanism allowing the establishment of persistent viral infections in ticks is still unknown.  
32 Hazara virus (HAZV) can be used as a BSL-2 model virus instead of CCHFV to study virus/vector  
33 interactions. To investigate the mechanism behind the establishment of a persistent infection, we  
34 developed an *in vitro* model with *Hyalomma*-derived tick cell lines and HAZV. As expected,  
35 HAZV, like CCHFV, persistently infects tick cells without any sign of cytopathic effect, and the  
36 infected cells can be cultured for more than three years. Most interestingly, we demonstrated the  
37 presence of short viral-derived DNA forms (vDNAs) after HAZV infection. Furthermore, we  
38 demonstrated that the antiretroviral drug AZT could inhibit the production of vDNAs, suggesting  
39 that vDNAs are produced by an endogenous retrotranscriptase activity in tick cells. Moreover, we  
40 collected evidence that vDNAs are continuously synthesized, thereby downregulating viral  
41 replication to promote cell survival. Finally, vDNAs were also detected in CCHFV-infected tick  
42 cells. In conclusion, vDNA synthesis might represent a strategy to control the replication of RNA  
43 viruses in ticks allowing their persistent infection.

44

45

46 **IMPORTANCE.**

47 Crimean-Congo hemorrhagic fever (CCHF) is an emerging tick-borne viral disease caused by  
48 CCHF virus (CCHFV). Ticks of the genus *Hyalomma* can be persistently infected with CCHFV  
49 representing the viral reservoir, and the main vector for viral transmission. Here we showed that  
50 tick cells infected with Hazara virus, a nonpathogenic model virus closely related to CCHFV,  
51 contained short viral-derived DNA forms (vDNAs) produced by endogenous retrotranscriptase

52 activity. vDNAs are transitory molecules requiring viral RNA replication for their continuous  
53 synthesis. Interestingly, vDNA synthesis seemed to be correlated with downregulation of viral  
54 replication and promotion of tick cell viability. We also detected vDNAs in CCHFV-infected tick  
55 cells suggesting that they could represent a key element in the cell response to nairovirus infection  
56 and might represent a more general mechanism of innate immunity against RNA viral infection.

57 **Keywords:**

58 Crimean–Congo hemorrhagic fever virus, Hazara virus, tick cell line, tick, viral-derived DNA  
59 forms, Orthonairovirus, tick-borne disease

60

61 **INTRODUCTION**

62 Crimean-Congo hemorrhagic fever (CCHF) is an emerging tick-borne viral disease widely  
63 distributed across Africa, Southern Europe, the Middle East and Asia (1). It is considered to be one  
64 of the major emerging disease threats spreading to, and also within, the European region following  
65 increasing circulation of its main vectors, ticks of the genus *Hyalomma* (2). Furthermore, CCHF is  
66 included in the WHO List of Blueprint priority diseases (3). CCHF is caused by Crimean-Congo  
67 hemorrhagic fever virus (CCHFV), which belongs to the genus *Orthonairovirus* of the recently-  
68 established family *Nairoviridae* (4). CCHFV is characterized by an enzootic cycle in asymptomatic  
69 mammals and ticks, while human infection represents an accidental event. Although 85% of human  
70 cases are subclinical, in symptomatic patients infection begins with fever and other nonspecific  
71 clinical signs, and can progress to a serious hemorrhagic syndrome with a case fatality rate up to  
72 30% (5, 6).

73 Although CCHFV has been detected in many tick species, *Hyalomma* ticks represent the main  
74 vectors of the virus and the natural reservoir. In fact, *Hyalomma* ticks feeding on a viremic host  
75 become persistently infected with CCHFV, the virus survives through the subsequent stages of the  
76 tick life cycle, and transovarial transmission occurs in this genus (7). To date, very limited  
77 information is available about the replication and persistence of CCHFV in ticks due to the

78 requirement for the virus to be handled in high-containment laboratories, compounded by the  
79 difficulty in manipulation of infected ticks in a biosafety level (BSL)-4 facility (7, 8). However, we  
80 have recently developed a CCHFV infection model based on embryo-derived *Hyalomma*  
81 *anatolicum* cell lines, providing the opportunity to study virus-vector interaction in an easier-to-  
82 handle *in vitro* system (9, 10).

83 Hazara virus (HAZV), originally isolated from a pool of adult *Ixodes redikorzevi* ticks removed  
84 from a vole in Pakistan (11), is a member of the family *Nairoviridae* and is closely related to  
85 CCHFV. Although genome sequence analyses clustered CCHFV and HAZV in different species,  
86 HAZV was classified in the same serogroup as CCHFV, based on antibody cross-reactivity between  
87 antigens of the two viruses (12, 13). Studies reported that CCHFV and HAZV have similar  
88 biological characteristics in terms of replication, interaction with cellular partners, and modulation  
89 of apoptosis (14–21). Although HAZV is able to simulate a disease similar to that induced by  
90 CCHFV in an interferon-deficient mouse model, it has never been associated with human disease  
91 and is considered a non-pathogenic virus that can be manipulated under BSL-2 conditions (22).

92 In the present study, we investigated virus/host interactions and possible mechanisms allowing the  
93 establishment of a persistent infection in ticks by applying HAZV, as a safe surrogate for CCHFV,  
94 to our tick cell line model. Interestingly, we showed that viral infection is associated with the  
95 synthesis of small viral-derived DNA forms (vDNAs), produced by a cellular reverse-transcriptase  
96 activity, that are required to suppress viral replication and thereby maintain tick cell viability.

97 Finally, we confirmed that vDNAs were also detectable in CCHFV-infected tick cells supporting  
98 the hypothesis that they could represent a key element in the cellular response to nairovirus  
99 infection. vDNAs might be involved in a general mechanism of innate immunity to counteract RNA  
100 virus infections in ticks.

101

## 102 **RESULTS**

103           **HAZV persistently infects *Hyalomma*-derived tick cell lines.** To investigate whether  
104 HAZV is able to productively infect *Hyalomma*-derived tick cell lines, the *H. anatolicum* cell lines  
105 HAE/CTVM8 and HAE/CTVM9 (23) were infected with HAZV at a multiplicity of infection  
106 (MOI) of 0.1 or 1.0. Viral replication was monitored by progeny titration and by evaluating the  
107 intracellular viral RNA yield using a quantitative real-time RT-PCR (qRT-PCR) approach. Titration  
108 of viral progeny in supernatants collected on days 1, 2, 3, 4 and 7 post infection (p.i.) showed that  
109 HAZV can productively infect *H. anatolicum* cells (Fig. 1A). The kinetics of viral progeny release  
110 were slightly different in the two cell lines; production of infectious viral particles was faster in  
111 HAE/CTVM9 than in HAE/CTVM8 cells. However, at 7 days p.i., prior to subculturing the  
112 infected cells, similar HAZV titers were observed in both cell lines (Fig. 1A). No viral particles  
113 were detected in supernatants of mock-infected cells (data not shown). The qRT-PCR results  
114 confirmed that replication of HAZV was slower in HAE/CTVM8 than in HAE/CTVM9 cells (Fig.  
115 1B). Starting from day 7 p.i., infected tick cell cultures were split every 7-10 days. HAZV was  
116 detected in subcultures by viral titration for 70 days suggesting the establishment of a persistent  
117 infection (Fig 1A).

118           To rule out the possibility that the different pattern of viral replication observed at the early  
119 time points (days 2-4 p.i.) was independent of an effect of the virus on cell viability, HAZV-  
120 infected HAE/CTVM8 and HAE/CTVM9 cells were monitored by phase-contrast microscopy and  
121 an MTT assay was used to evaluate cellular metabolic activity as a measure of viability. HAZV-  
122 infected human SW13 cells were used as positive control cells killed by the virus. In fact, HAZV  
123 efficiently replicates in SW13 cells (14, 17) producing a robust cytopathic effect as described for  
124 CCHFV (18). As expected, the metabolic activity of SW13 cells rapidly decreased over time after  
125 viral infection for both MOIs tested (Fig. 1C). In contrast, microscopic analysis of tick cell cultures  
126 (data not shown) and MTT assay performed at 2, 4, and 7 days p.i. did not detect any significant  
127 effect on the tick cells even at day 7 (Fig. 1C) suggesting that the HAZV infection did not affect  
128 tick cell viability.

129 Taking into account that HAE/CTVM8 cells showed similar kinetics of replication for HAZV and  
130 CCHFV (9) and grew more reliably in our hands than HAE/CTVM9 cells, we focused our attention  
131 on this cell line for the subsequent experimental steps.

132 To further characterize the generation of the persistently-infected HAE/CTVM8 cells, we firstly  
133 evaluated the percentage of HAZV-infected cells during the initial stages of infection by  
134 challenging HAE/CTVM8 cells with HAZV at MOI 0.1. Next, we evaluated infected cells over  
135 time by immunostaining of viral nucleoprotein (N). As shown in Figure 2A, the proportion of N-  
136 expressing cells increased from ~43% at day 6 p.i. to ~62% at day 15 p.i., while at later time points,  
137 when cells are persistently infected, almost all cells stained positive (Fig 2A – panel showing  
138 persistently infected cells). In addition, we confirmed that HAZV did not kill infected cells, as  
139 demonstrated by similar growth kinetics of virus-infected and mock-infected control cells (Fig. 2B).  
140 These observations suggest that the virus was slowly spreading throughout the culture from an  
141 initially low number of infected cells. The persistence of HAZV was further confirmed in infected  
142 HAE/CTVM8 cells by RT-PCR at 15, 30, 60, 312, and 715 days p.i. (data not shown) and by the  
143 titration of infectious viral progeny (Fig. 2C) indicating continued active viral replication. Persistent  
144 infection of HAE/CTVM8 cells was achieved on three independent occasions and one of the  
145 persistently-infected cultures was maintained for more than three years.

146

147 **Viral-derived DNA forms are detectable in *de novo* infected and persistently-infected tick**  
148 **cells.** It has been recently reported that in some insect cells RNA virus infection is associated with  
149 the synthesis of vDNAs that are involved in the establishment of persistent infection (24, 25). To  
150 determine whether HAZV infection of tick cells was associated with the formation of vDNAs,  
151 HAE/CTVM8 and HAE/CTVM9 cell were infected with HAZV at MOI 0.1 and 1.0 and the  
152 formation of vDNAs was evaluated by PCR. To this end, nine pairs of primers, designed to amplify  
153 overlapping sequences of 152-237 bp covering the S segment of the HAZV genome, were adopted  
154 (Fig. 3A). Specific PCR amplicons were already obtained from total DNA extracted from infected

155 tick cells at day 1 p.i., with a maximum number of fragments detected at 7 days p.i. (Fig. 3B-C). No  
156 vDNAs were detected in mock-infected tick cells or, more significantly, in HAZV-infected  
157 mammalian Vero cells (data not shown). Furthermore, while RNase treatment of infected cell DNA  
158 extracts did not affect amplification of vDNAs, when DNase was added no PCR products were  
159 detected (data not shown). Finally, when combining the primers of contiguous amplicons, we did  
160 not detect fragments larger than ~240 bp, suggesting that each vDNA represent only a small portion  
161 of the viral genome segment, and that neither long fragments nor the entire genome segment were  
162 synthesized (data not shown). Overall, these results suggest that vDNAs are small DNA fragments  
163 likely derived from the HAZV genome.

164 Interestingly, vDNAs were constantly detectable in persistently-infected tick cell cultures, as the  
165 presence of vDNAs was periodically confirmed by PCR (up to 10 times per year; data not shown)  
166 suggesting that they either represent stable molecules or are continuously synthesized during cell  
167 culture.

168

169 **vDNA synthesis depends on viral RNA replication and is mediated by a cellular reverse-**  
170 **transcriptase activity**

171 To investigate whether viral RNA replication is required for vDNA synthesis, HAE/CTVM8  
172 cells were infected with UV-inactivated HAZV. Three days later, total DNA was extracted and  
173 submitted to PCR analyses and no vDNAs were detected (data not shown). Furthermore,  
174 HAE/CTVM8 cells, persistently infected for at least 6 months, were treated with ribavirin (100  
175 mM), a drug known to inhibit viral genome replication. As expected and shown in Figure 4 A and B,  
176 viral progeny production was suppressed and the yield of intracellular viral RNA decreased. In this  
177 experimental condition, at 72 h post treatment, vDNAs disappeared suggesting that viral RNA  
178 replication is required for vDNA synthesis (Fig 4C).

179 In the case of RNA viruses lacking a viral enzyme able to convert genomic RNA to DNA,  
180 the formation of vDNAs could be due to the presence of endogenous reverse transcriptases (RTs)

181 encoded by retrotransposons and/or endogenous retroviruses integrated into the genome of tick cells.  
182 By performing an RT assay, we detected a clear  $Mn^{2+}$  dependent RT-activity in HAE/CTVM8 cell  
183 lysates, with a slightly higher level in HAE/CTVM8 cells persistently infected with HAZV (cells  
184 cultured for more than 6 months) compared to uninfected cells (Fig. 5A). Furthermore, to  
185 demonstrate that vDNAs were synthesized by cellular RT activity, we treated HAE/CTVM8 cells  
186 with the nucleoside RT inhibitor azidothymine triphosphate (AZT). Specifically, 5 mM AZT was  
187 selected, as this concentration did not significantly affect cell viability (see next paragraph) and had  
188 been already adopted to treat insect cells (24, 25). In addition, three different schedules of AZT  
189 administration were adopted: 1) 6 h before virus infection; 2) at the time of viral infection; 3) 6 h  
190 before virus infection as well as at the time of infection (Fig. 5B). As shown in Fig. 5C, while a  
191 reduction up to 30% in vDNA yield was observed when cells were treated with AZT before viral  
192 infection (experimental condition 1), this reduction increased up to 50% when the drug was added  
193 during the viral adhesion step (experimental condition 2). A stronger effect (roughly 70% reduction)  
194 resulted from the combination of the two treatments (experimental condition 3). Overall, these  
195 results suggest that a cellular RT activity is required for the synthesis of vDNA.

196

### 197 **vDNAs promote suppression of viral particle production and survival of HAZV-infected tick** 198 **cells**

199 To evaluate the effect of vDNAs on HAZV infection in tick cells, we treated persistently-  
200 infected (>1 year of culture) HAE/CTVM8 cells with 5 mM AZT. Seventy-two hours later, the viral  
201 titer obtained from treated cells was roughly 4 times higher than the one obtained from untreated  
202 cells. Furthermore, the number of vDNAs in treated cells was roughly one-third of that seen in the  
203 untreated cells (Fig. 6A-B). By contrast, the yield of intracellular viral RNA was not affected by  
204 AZT treatment, suggesting that AZT does not interfere with viral genome replication (Fig. 6C).  
205 However, immunostaining (Fig. 6D) revealed a clear increase of the amount of HAZV N protein  
206 (increase of fluorescence intensity) in AZT-treated cells, which was quantified by western blotting



207 as 1.5 times greater than that in control cells (Fig. 6E), suggesting a higher level of N protein  
208 synthesis.

209 Interestingly, an MTT assay showed a significant decrease in the metabolism of AZT-treated cells  
210 (Fig. 7A), associated with the increase in viral titer. To demonstrate that the reduction in cell  
211 metabolism was associated with viral-mediated cell death, uninfected and persistently-infected  
212 HAE/CTVM8 cells were treated with AZT and the number of live cells was counted by trypan blue  
213 exclusion assay. Although the AZT caused a slight reduction in the number of uninfected cells over  
214 a 72 h period, a significant decrease in live cell numbers was observed only in persistently-infected  
215 cells (Fig. 7B).

216 In conclusion, our data suggest that vDNAs might contribute to controlling HAZV infection in tick  
217 cells by suppressing the production of infectious viral progeny and, thereby, promoting the survival  
218 of infected cells.

#### 219 220 **vDNAs are detectable in CCHFV-infected HAE/CTVM8 tick cells**

221 We have previously demonstrated that CCHFV can persistently infect *Hyalomma*-derived  
222 tick cell lines (9). To demonstrate that CCHFV infection induces vDNA formation in tick cells,  
223 HAE/CTVM8 cells were infected with CCHFV at MOI 0.1 and harvested at 3 and 7 days p.i.. As  
224 for HAZV, we designed a panel of primers covering the entire S segment of CCHFV and the PCR  
225 analyses on total DNA extracted from infected cells demonstrated the presence of vDNAs (Fig. 8).  
226 This result suggests that vDNA production could be a common tick cellular response following  
227 RNA virus infection, as reported for some insects (26).

#### 228 229 **DISCUSSION**

230 CCHFV is the most important and globally-widespread tick-borne hemorrhagic fever virus and its  
231 emergence and re-emergence highlight the importance of this infectious agent for human health (1).

232 Despite the rapid increase in knowledge of viral biology and the development of diagnostic tools in  
233 the last decade (2), there is still a large gap in the characterization of virus/vector interaction.  
234 We and others have shown that CCHFV can persistently infect ticks and tick cell lines without  
235 deleterious effects (7, 9, 10, 27, 28); however, the mechanism allowing the persistent infection of  
236 CCHFV (and other tick-borne viruses) in ticks has not yet been characterized.

237 In the present study, we adopted HAZV as a non-pathogenic surrogate for CCHFV, with the aim of  
238 studying the mechanisms involved in the establishment of persistent infection of tick vectors.

239 Firstly, we showed that HAZV replicates productively in cell lines derived from tick of a genus  
240 (*Hyalomma*) that was never reported to function as a vector for HAZV (29). In addition, the HAZV  
241 infection did not appear to be cytopathic for tick cells and persisted for a long time, as previously  
242 reported in the case of CCHFV and other tick-borne viruses (9, 10, 27, 30–32). It is notable that  
243 HAZV showed kinetics of replication in *H. anatolicum* cell lines faster than those previously  
244 reported for CCHFV in the same cell lines (9, 27) and produced higher viral titers, suggesting that  
245 *Hyalomma* ticks could support HAZV infection (27).

246 Previously, Goic and co-workers demonstrated that short vDNAs were detected *in vitro* and *in vivo*  
247 in insect cells infected by RNA viruses and that they were involved in the control of virus  
248 replication allowing persistent infection of cultured cells and insects (24, 25). Remarkably, we  
249 detected vDNAs in HAZV-infected tick cells from as early as 24 h p.i.. Considering that  
250 nairoviruses do not encode a viral RT, the RT-activity required for vDNA synthesis could be  
251 provided by endogenous cellular sequences (i.e. retrotransposons and retroviral sequences). No  
252 genome sequences are as yet available for any *Hyalomma* spp. ticks; however a reverse  
253 transcriptase-like protein has been described in *Amblyomma americanum* (UniProtKBQ49P04)  
254 while RT activity was detected in three *Ixodes scapularis* embryo-derived cell lines (33), thus  
255 supporting the possibility of RT expression also in *Hyalomma* derived cell lines. In fact, we  
256 detected Mn<sup>2+</sup> dependent RT-activity in HAE/CTVM8 cell lysates, and experiments with the RT

257 inhibitor AZT showed that RT is involved in vDNA synthesis in tick cells, as described for insect  
258 cells (24, 25).

259 Moreover, our data showed that vDNAs are always detectable in persistently-infected tick cells and  
260 the S segment can be fully used as template for their synthesis. In contrast, Nag and co-workers  
261 reported that only two regions of the S segment of La Crosse virus (LACV), another member of the  
262 order *Bunyavirales*, were detectable in infected C6/36 insect cells (34). This apparent discrepancy  
263 between HAZV and LACV might be due to biological differences between the two viruses. On the  
264 other hand, it should be taken into account that those authors adopted a different PCR strategy, not  
265 based on multiple small overlapping amplicons. Furthermore, they analyzed vDNA presence only at  
266 one time point after viral infection, a choice that might have negatively impacted the efficiency of  
267 detection (34). Interestingly, we observed that vDNA amplification depends on active viral RNA  
268 replication, suggesting that vDNAs are not stable but are continuously synthesized during the  
269 persistent infection of tick cells.

270 Reports on insect RNA viruses suggest that vDNAs may be produced via template-switching events,  
271 when the RT switches from the retro-elements template to viral RNA forming linear and episomal  
272 vDNA-retrotransposon chimeric molecules, while integration events into the genome are rare (24,  
273 25, 35, 36). However, the integration of viral sequences into the arthropod genome, although  
274 infrequently detected to date, is considered important in virus/vector co-evolution (10, 37–39). In  
275 fact, many bunya- and othomyxo-like sequences have been identified in the *I. scapularis* genome  
276 suggesting that these viruses can produce vDNAs in ticks and occasionally integrate into the  
277 genome of germline cells (40).

278 The modulation of virus replication mediated by vDNAs in insects is based on an RNAi  
279 mechanism; it has been shown that vDNAs are transcribed and used as templates for the synthesis  
280 of short RNAs that suppress viral replication (24, 25, 34, 36, 41). Our data are compatible with this  
281 mechanism. In fact, we observed that: i) the proportion of infected cells increased over time during  
282 the infection while viral titer decreased; ii) the inhibition of vDNA synthesis by AZT treatment was

283 associated with an increase in nucleoprotein yield and viral titer without any effect at the level of  
284 intracellular viral RNA, thus suggesting post-transcriptional regulation. However, at this stage, a  
285 contribution of specific effects on viral genome replication/transcription efficiency cannot be fully  
286 ruled out.

287 The above-described model of vDNA production is compatible with the requirement of active viral  
288 RNA replication for vDNA synthesis; continuous virus replication allows the production of RNA  
289 templates and the chance of switching events producing new vDNAs. On the other hand, vDNAs  
290 may mediate a suppressive effect on virus replication, reducing virus proteins and progeny release,  
291 thus inducing an equilibrium between virus replication and generation of new vDNAs.

292 More interestingly, inhibition of vDNA synthesis induced a reduction in cell viability, as showed by  
293 MTT and by the proportion of live cells. According to the literature on insect RNA viruses, increase  
294 of viral assembly and budding could be associated with a cytotoxic effect, negatively affecting cell  
295 survival (24, 25).

296 Although more research is required to further characterize the biology of vDNA production and  
297 function, our *in vitro* data supported the view that vDNAs are linked to the establishment of  
298 persistent viral infections, reducing the production of viral progeny and protecting tick cells from  
299 deleterious effects. *In vivo* experiments could investigate the relevance of vDNA inhibition for tick  
300 survival, as demonstrated in the case of mosquitoes infected with arboviruses (24, 25). Indeed, the  
301 development of tools to interfere with vDNA synthesis might represent a strategy to reduce the  
302 fitness of infected ticks and lower the risk of transmission of the virus in endemic areas.

303 In conclusion, we show for the first time that vDNAs are detectable in tick cells infected with  
304 HAZV and CCHFV. As described for insect-borne RNA viruses, vDNAs seem to be associated  
305 with the establishment of persistent infection in ticks, which are classified in a different subphylum  
306 of the *Arthropoda* from insects. Also, in this context vDNAs appear to control viral replication and  
307 promote cell survival, thus allowing persistence of the virus in the environment. Overall these

308 findings suggest that vDNA synthesis might represent a common strategy to control viral infections  
309 in arthropods.

310

## 311 **MATERIALS AND METHODS**

312 **Cells and viruses.** All culture media and supplements were obtained from Gibco unless otherwise  
313 indicated. SW13 cells (human adrenal cortex adeno-carcinoma cells, ATCC® CCL-105™), were  
314 cultured in Leibovitz's L-15 medium (L-15) supplemented with 10% heat-inactivated fetal bovine  
315 serum (FBSi) and 100 U/mL penicillin and 100 µg/mL streptomycin (p/s). Vero cells (African  
316 green monkey kidney cells, ATCC® CCL-81) were grown in Dulbecco's modified Eagle's medium  
317 (D-MEM) containing 10% FBSi and p/s. Vero cells were maintained at 37 °C in a humidified  
318 atmosphere of 5 % CO<sub>2</sub> in air while SW13 cells were maintained at 37 °C in ambient air.

319 The *H. anaticum* embryo-derived cell lines HAE/CTVM8 and HAE/CTVM9 were grown in,  
320 respectively, L15/H-Lac medium (equal volumes of L-15 supplemented with 10% tryptose  
321 phosphate broth [TPB] and Hank's balanced salt solution with 0.5% lactalbumin hydrolysate  
322 [Sigma]) and L-15/MEM medium (equal volumes of L-15 and Minimal Essential Medium with  
323 Hank's salts supplemented with 10% TPB), both supplemented with 2 mM L-glutamine, 20% FBSi  
324 and p/s, and incubated in sealed flat-sided culture tubes (Nunc, Thermo-Fisher Scientific) in  
325 ambient air at 32 °C (23).

326 Uninfected and HAZV-infected SW13 and tick cell metabolic activity was tested with an assay  
327 based on the reduction of a tetrazolium salt (MTT Cell Proliferation Assay ATCC ® 30-1010K™)  
328 in a 96-well plate format according to the manufacturer's instructions. Tick cells were grown in  
329 sealed 96-well plates for the MTT assay.

330 The HAZV JC280 and the CCHFV IbAr10200 strains produced in SW13 cells were used in the  
331 experiments (21).

332

333 **Viral stock preparation.** SW13 cells were seeded in T75 flasks and then infected with HAZV or  
334 CCHFV (MOI of ~ 0.1). At 48-72 h p.i., supernatants were collected, centrifuged at  $896 \times g$  for 10  
335 min, then 10-fold serially diluted in L-15 with 2% FBSi and titrated on Vero cells in 96-well plates.  
336 After 24 h incubation, cells were fixed with methanol-acetone and stained for immunofluorescence  
337 assay using a rabbit polyclonal anti-CCHFV nucleoprotein antibody (21), that also recognized  
338 HAZV-N, and Alexa Fluor™ 488 goat anti-rabbit IgG (Invitrogen), according to the  
339 manufacturer's instructions. The fluorescent foci in each well were counted and viral titer was  
340 expressed as focus-forming units per mL (FFU)/mL.

341

342 **Infection of tick cell lines.** Tick cells ( $2 \times 10^6$ ) were seeded in flat-sided tubes and cultured for 48 h  
343 in 2.5 mL of complete medium. Then, 1.5 mL medium was removed and retained, and cells were  
344 incubated for 1 h with HAZV, at the appropriate MOI, in a final volume of ~1 mL of complete  
345 medium. Cells were carefully washed once with phosphate-buffered saline (PBS) and cultured in  
346 2.5 mL of conditioned medium (retained old medium and fresh medium in a ratio of 1:2). In studies  
347 of kinetics of viral progeny release, 200  $\mu$ L of supernatant medium were collected at the appropriate  
348 time points for viral titration on Vero cells as above, and an equal volume of fresh medium was  
349 replaced in the culture tubes. To evaluate the viral RNA yield, cells were harvested, centrifuged at  
350  $7,168 \times g$  for 10 min and washed once with PBS before lysis.

351 Infections of tick cells with UV-inactivated HAZV were performed using a viral stock inactivated  
352 as previously described (42). Briefly, an aliquot of 1 ml virus stock in a well of a 6-well plate was  
353 irradiated with UV (UV Mineral light lamp, model UVG-54, 254 nm, UVP, Upland, CA) at a  
354 distance of 17 mm for 1 min.

355

356 **Immunostaining.** Tick cells were collected and centrifuged at  $206 \times g$  for 7 min and washed once  
357 with PBS, and finally resuspended in PBS. Cells ( $0.6 \times 10^6$  in 200  $\mu$ L) were applied to cleaned  
358 microscope slides using a Shandon III cytocentrifuge (3 min at 1000 rpm). After centrifugation,

359 cells were fixed in 70% ethanol at 4 °C for 30 min and an immunofluorescence assay was  
360 performed. Nonspecific sites were blocked using 2.5% bovine serum albumin (BSA, Sigma) in PBS  
361 and incubation for 1 h at room temperature. Subsequently, slides were incubated for 1.5 h at 37 °C  
362 with the above-mentioned anti-N antibody diluted 1:200 in PBS with 2.5% BSA and 0.1% Tween  
363 20. After this incubation, slides were washed with PBS and incubated for 1 h at 37 °C in the dark  
364 with Alexa Fluor™ 488 goat anti-rabbit IgG (Invitrogen) diluted 1:1000 in PBS with 2.5% BSA  
365 and 0.1% Tween 20, and nuclei were stained with a 1:1000 dilution of 5mM DRAQ5 solution  
366 (Thermo-Fisher Scientific).

367 After this last incubation, infected and mock-infected control cells were examined under a Nikon  
368 A1RSi Laser Scanning inverted confocal microscope equipped with NIS-Elements Advanced  
369 Research software (Nikon Instruments Inc., Tokyo, Japan) and blue (488 nm) and green (561 nm)  
370 lasers.

371

372 **Western blot analysis.** Tick cell cultures were harvested and washed in PBS by centrifugation at  
373  $335 \times g$  for 7 min at 4 °C and then lysed in 100  $\mu$ l of 1X radioimmunoprecipitation assay (RIPA)  
374 buffer (PBS containing 1 % Nonidet P-40, 0.5 % deoxycholate and 0.05 % SDS) in the presence of  
375 protease inhibitors (0.1 mM N $\alpha$ -p-tosyl-L-lysine chloromethyl ketone, 0.1 mM tosylsulfonyl  
376 phenylalanyl chloromethyl ketone, Complete Protease Inhibitor Cocktail Tablets, Roche). Samples  
377 were boiled for 5 min at 100 °C and directly resolved by sodium dodecyl sulfate-polyacrylamide gel  
378 electrophoresis (4.5% stacking gel and 10% resolving gel). Proteins were electroblotted onto a  
379 Hybond ECL nitrocellulose membrane (GE Healthcare Life Sciences). The N protein was detected  
380 by employing the above-mentioned rabbit polyclonal anti-CCHFV nucleoprotein antibody followed  
381 by anti-rabbit HRP-conjugated IgG. The loading control was evaluated using a rabbit polyclonal  
382 anti-calnexin antibody (In-house, Agrisera). Blots were developed with enhanced  
383 chemiluminescence reagents (Amersham Pharmacia) (43). Western blot quantification was

384 performed using the software provided with the Alliance Q9 advanced chemiluminescence imager  
385 (Uvitec; Cleaver Scientific).

386

387 **Drug treatments.** AZT (Sigma) was dissolved in DMSO to a final concentration of 5M while  
388 ribavirin (Sigma) was dissolved in ultrapure H<sub>2</sub>O (MilliQ, Merck) to a final concentration of  
389 100mM. Aliquots were stored at -20 °C. For treatment of cell cultures, half the volume of culture  
390 medium was removed and replaced with fresh medium containing the drug. Cells were incubated  
391 until the indicated time points. Then, cells were detached by pipetting, centrifuged at 2,205 × g for  
392 10 min and washed once with PBS. Cell pellets were then processed for DNA or RNA extraction.

393

394 **Nucleic acid isolation and qRT-PCR analysis.** DNA and RNA were extracted using a DNeasy  
395 Blood & Tissue Kit and a RNeasy Mini Kit (Qiagen) respectively, according to the manufacturer's  
396 instructions. HAZV RNA was amplified using the Superscript III Platinum One-step kit  
397 (Invitrogen) following the standard PCR conditions for TaqMan probes using primers and probe  
398 targeting the S segment (21). Kinetics of intracellular viral RNA replication were evaluated using  
399 the  $\Delta\Delta C_t$  method for the relative quantification of RNA (set to 1 at day 0) using the putative  
400 translation elongation factor EF-1 alpha/Tu endogenous gene of *H. anatolicum* tick cells to  
401 normalize the viral RNA (9, 44).

402 The yield of intracellular HAZV RNA in the ribavirin and AZT experiments was evaluated using a  
403 standard curve generated from six serial dilutions (from  $5 \times 10^6$  to 50 copies) of a control plasmid  
404 containing the region amplified by the primers. The HAZV RNA copy number of the samples was  
405 calculated automatically with the software of the ABI 7900HT Sequence Detection Systems  
406 (Thermo Fisher Scientific) and then expressed as numbers of viral RNA copies per 0.2  $\mu$ g of total  
407 RNA.

408

409 **Detection of vDNAs**



410 PCRs were performed on total DNA extracted from infected HAE/CTVM8 cells with nine pairs of  
411 primers mapping within the S segment of the HAZV genome (GenBank: KP406725.1) and the  
412 CCHFV genome (GenBank: U88410.1). Primers used in this study were designed using the  
413 program “Primer3” available online (<http://bioinfo.ut.ee/primer3-0.4.0/>). The primer sequences are  
414 available on request.

415 Each PCR reaction mixture contained 5  $\mu$ L of 10 $\times$  PCR buffer with 15 mM MgCl<sub>2</sub>, 1  $\mu$ L of 0.625  
416 mM dNTPs mix, 2  $\mu$ L of each primer (10  $\mu$ M), 0.5  $\mu$ L of TaqGold, 50 ng of DNA and PCR grade  
417 water up to the final reaction volume of 50  $\mu$ L (all reagents were purchased from Thermo  
418 Scientific). Cycling conditions were: 1 cycle of 10 min at 95  $^{\circ}$ C; 40 cycles of 15 s at 95  $^{\circ}$ C, 30 s at  
419 60  $^{\circ}$ C and 45 s at 72  $^{\circ}$ C; 5 min at 72  $^{\circ}$ C. Twenty microliters of each PCR product were loaded onto  
420 a 2% (w/v) agarose gel containing the GelRed<sup>®</sup> Nucleic Acid Gel Stain (Biotium).

421

#### 422 ***In vitro* reverse transcriptase assay**

423 To extract proteins, cells were lysed in CHAPS lysis buffer (10 mM Tris-HCl pH 7.5, 400 mM  
424 NaCl, 0.7 mM MnCl<sub>2</sub>, 1mM MgCl<sub>2</sub>, 1mM EGTA, 0.5% CHAPS, 10% glycerol, freshly  
425 supplemented with complete EDTA-free protease inhibitors cocktail [Roche] and 1mM DTT). After  
426 incubation at 4  $^{\circ}$ C for 10 min, cell debris was removed by centrifugation at 16,900  $\times$  g for 10 min at  
427 4  $^{\circ}$ C. Supernatants were transferred to clean tubes. Total protein concentration was determined  
428 using a Micro BCA protein Assay Kit (Thermo Scientific) following the manufacturer’s instructions.  
429 Reverse transcriptase assays were carried out for 15 min at 25  $^{\circ}$ C in a total reaction volume of 50  $\mu$ L  
430 containing 4  $\mu$ g of protein sample, 320 ng of PAGE-purified oligo(dT)<sub>18</sub>, 500 ng of poly(rA), and 1  
431  $\mu$ L of 84 Ci/mmol 3H-dTTP in 50 mM Tris-HCl (pH 7.5), 50 mM KCl, 5mM MgCl<sub>2</sub>, 5mM DTT  
432 and 0.1% Triton X-100. After this, the entire 50  $\mu$ L of each reaction was spotted on an ion paper  
433 (Amersham Hybond-N+, GE Healthcare) that retains incorporated nucleotides but not free dNTPs.  
434 Papers were washed 3 times (10 min for each wash) with saline-sodium citrate buffer (0.3 M NaCl,

435 0.03 M sodium citrate pH 7.2) and immersed in 4 mL of liquid scintillation cocktail Ultima Gold™  
436 (PerkinElmer). Radioactivity was measured using a Scintillator (TRI-carb 2819 TR, Perkin Elmer).

437

438 **Statistical analyses.** Graphs and statistical comparisons, applying Student's t-test, were performed  
439 with the GraphPad Prism 8 software (21). Data subjected to statistical analyses have been replicated  
440 in at least 3 independent experiments. Differences were considered to be statistically significant at p  
441 < 0.05.

442

#### 443 **ACKNOWLEDGMENTS**

444 The tick cell lines HAE/CTVM8 and HAE/CTVM9 were provided by the Tick Cell Biobank.

445 This work was supported by University of Padova grants (DOR 2017-2019 and PRID 2017) to CS,

446 ArboNET (2015–01885), Swedish Research Council grants (2017–03126) to AM, and United

447 Kingdom Biotechnology and Biological Sciences Research Council grants BB/N023889/2 and

448 BB/P024270/1 to LB-S. M.V.S was supported by a fellowship of the PhD School in Molecular

449 Medicine, University of Padova.

450

#### 451 **REFERENCES**

452 1. Spengler JR, Bente DA, Bray M, Burt F, Hewson R, Korukluoglu G, Mirazimi A, Weber F,

453 Papa A. 2018. Second International Conference on Crimean-Congo Hemorrhagic Fever.

454 *Antiviral Res* 150:137–147.

455 2. Papa A, Mirazimi A, Köksal I, Estrada-Pena A, Feldmann H. 2015. Recent advances in

456 research on Crimean-Congo hemorrhagic fever. *J Clin Virol* 64:137–143.

457 3. Mehand MS, Al-Shorbaji F, Millett P, Murgue B. 2018. The WHO R&D Blueprint: 2018

458 review of emerging infectious diseases requiring urgent research and development efforts.

459 *Antiviral Res* 159:63-67.

460 4. Maes P, Alkhovsky S V., Bào Y, Beer M, Birkhead M, Briese T, Buchmeier MJ, Calisher

461 CH, Charrel RN, Choi IR, Clegg CS, de la Torre JC, Delwart E, DeRisi JL, Di Bello PL, Di  
462 Serio F, Digiario M, Dolja V V., Drosten C, Druciarek TZ, Du J, Ebihara H, Elbeaino T,  
463 Gergerich RC, Gillis AN, Gonzalez JPJ, Haenni AL, Hepojoki J, Hetzel U, Hồ T, Hóng N,  
464 Jain RK, Jansen van Vuren P, Jin Q, Jonson MG, Junglen S, Keller KE, Kemp A, Kipar A,  
465 Kondov NO, Koonin E V., Kormelink R, Korzyukov Y, Krupovic M, Lambert AJ, Laney  
466 AG, LeBreton M, Lukashevich IS, Marklewitz M, Markotter W, Martelli GP, Martin RR,  
467 Mielke-Ehret N, Mühlbach HP, Navarro B, Ng TFF, Nunes MRT, Palacios G, Pawęska JT,  
468 Peters CJ, Plyusnin A, Radoshitzky SR, Romanowski V, Salmenperä P, Salvato MS,  
469 Sanfaçon H, Sasaya T, Schmaljohn C, Schneider BS, Shirako Y, Siddell S, Sironen TA,  
470 Stenglein MD, Storm N, Sudini H, Tesh RB, Tzanetakis IE, Uppala M, Vapalahti O,  
471 Vasilakis N, Walker PJ, Wáng G, Wáng L, Wáng Y, Wèi T, Wiley MR, Wolf YI, Wolfe ND,  
472 Wú Z, Xú W, Yang L, Yāng Z, Yeh SD, Zhāng YZ, Zhèng Y, Zhou X, Zhū C, Zirkel F,  
473 Kuhn JH. 2018. Taxonomy of the family Arenaviridae and the order Bunyavirales: update  
474 2018. *Arch Virol* 163:2295–2310.

475 5. Akıncı E, Bodur H, Leblebicioglu H. 2013. Pathogenesis of Crimean-Congo Hemorrhagic  
476 Fever. *Vector-Borne Zoonotic Dis* 13:429–437.

477 6. Bente DA, Forrester NL, Watts DM, McAuley AJ, Whitehouse CA, Bray M. 2013. Crimean-  
478 Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and  
479 genetic diversity. *Antiviral Res* 100:159–189.

480 7. Xia H, Beck AS, Gargili A, Forrester N, Barrett ADT, Bente DA. 2016. Transstadial  
481 Transmission and Long-term Association of Crimean-Congo Hemorrhagic Fever Virus in  
482 Ticks Shapes Genome Plasticity. *Sci Rep* 6:35819.

483 8. Thangamani S, Bente D. 2014. Establishing protocols for tick containment at Biosafety Level  
484 4. *Pathog Dis* 71:282–285.

485 9. Salata C, Monteil V, Karlberg H, Celestino M, Devignot S, Leijon M, Bell-Sakyi L,  
486 Bergeron É, Weber F, Mirazimi A. 2018. The DEVD motif of Crimean-Congo hemorrhagic

- 487 fever virus nucleoprotein is essential for viral replication in tick cells. *Emerg Microbes Infect*  
488 7:190.
- 489 10. Salata C, Moutailler S, Attoui H, Zweygarth E, Decker L, Bell-Sakyi L. 2021. How relevant  
490 are in vitro culture models for study of tick-pathogen interactions? *Pathog Glob Health*  
491 <https://doi.org/10.1080/20477724.2021.1944539>.
- 492 11. Begum F, Wisseman CL, Casals J. 1970. Tick-borne viruses of West Pakistan. II. Hazara  
493 virus, a new agent isolated from *Ixodes redikorzevi* ticks from the Kaghan Valley, W.  
494 Pakistan. *Am J Epidemiol* 92:192–194.
- 495 12. Kuhn JH, Wiley MR, Rodriguez SE, Bào Y, Prieto K, Travassos da Rosa APA, Guzman H,  
496 Savji N, Ladner JT, Tesh RB, Wada J, Jahrling PB, Bente DA, Palacios G. 2016. Genomic  
497 characterization of the genus nairovirus (Family Bunyaviridae). *Viruses* 8(6):164.
- 498 13. Kalkan-Yazıcı M, Karaaslan E, Çetin NS, Hasanoğlu S, Güney F, Zeybek Ü, Doymaz MZ.  
499 2021. Cross-Reactive Anti-Nucleocapsid Protein Immunity against Crimean-Congo  
500 Hemorrhagic Fever Virus and Hazara Virus in Multiple Species. *J Virol* 95(7):e02156-20.
- 501 14. Fuller J, Surtees RA, Shaw AB, Álvarez-Rodríguez B, Slack GS, Bell-Sakyi L, Mankouri J,  
502 Edwards TA, Hewson R, Barr JN. 2019. Hazara nairovirus elicits differential induction of  
503 apoptosis and nucleocapsid protein cleavage in mammalian and tick cells. *J Gen Virol*  
504 100:392–402.
- 505 15. Fuller J, Surtees RA, Slack GS, Mankouri J, Hewson R, Barr JN. 2019. Rescue of Infectious  
506 Recombinant Hazara Nairovirus from cDNA Reveals the Nucleocapsid Protein DQVD  
507 Caspase Cleavage Motif Performs an Essential Role other than Cleavage. *J Virol*  
508 93(15):e00616-19.
- 509 16. Matsumoto Y, Nouchi T, Ohta K, Nishio M. 2019. Regulation of Hazara virus growth  
510 through apoptosis inhibition by viral nucleoprotein. *Arch Virol* 164:1597–1607.
- 511 17. Surtees R, Dowall SD, Shaw A, Armstrong S, Hewson R, Carroll MW, Mankouri J, Edwards  
512 TA, Hiscox JA, Barr JN. 2016. Heat Shock Protein 70 Family Members Interact with

- 513 Crimean-Congo Hemorrhagic Fever Virus and Hazara Virus Nucleocapsid Proteins and  
514 Perform a Functional Role in the Nairovirus Replication Cycle. *J Virol* 90:9305–9316.
- 515 18. Karlberg H, Tan Y-J, Mirazimi A. 2011. Induction of Caspase Activation and Cleavage of  
516 the Viral Nucleocapsid Protein in Different Cell Types during Crimean-Congo Hemorrhagic  
517 Fever Virus Infection. *J Biol Chem* 286:3227–3234.
- 518 19. Karlberg H, Tan Y-J, Mirazimi A. 2015. Crimean-Congo haemorrhagic fever replication  
519 interplays with regulation mechanisms of apoptosis. *J Gen Virol* 96:538–546.
- 520 20. Carter SD, Surtees R, Walter CT, Ariza A, Bergeron E, Nichol ST, Hiscox JA, Edwards TA,  
521 Barr JN. 2012. Structure, Function, and Evolution of the Crimean-Congo Hemorrhagic Fever  
522 Virus Nucleocapsid Protein. *J Virol* 86:10914–10923.
- 523 21. Monteil V, Salata C, Appelberg S, Mirazimi A. 2020. Hazara virus and Crimean-Congo  
524 Hemorrhagic Fever Virus show a different pattern of entry in fully-polarized Caco-2 cell line.  
525 *PLoS Negl Trop Dis* 14:e0008863.
- 526 22. Dowall SD, Findlay-Wilson S, Rayner E, Pearson G, Pickersgill J, Rule A, Merredew N,  
527 Smith H, Chamberlain J, Hewson R. 2012. Hazara virus infection is lethal for adult type I  
528 interferon receptor-knockout mice and may act as a surrogate for infection with the human-  
529 pathogenic Crimean-Congo hemorrhagic fever virus. *J Gen Virol* 93:560–564.
- 530 23. Bell-Sakyi L. 1991. Continuous cell lines from the tick *Hyalomma anatolicum anatolicum*. *J*  
531 *Parasitol* 77:1006–1008.
- 532 24. Goic B, Vodovar N, Mondotte JA, Monot C, Frangeul L, Blanc H, Gausson V, Vera-Otarola  
533 J, Cristofari G, Saleh MC. 2013. RNA-mediated interference and reverse transcription  
534 control the persistence of RNA viruses in the insect model *Drosophila*. *Nat Immunol* 14:396–  
535 403.
- 536 25. Goic B, Stapleford KA, Frangeul L, Doucet AJ, Gausson V, Blanc H, Schemmel-Jofre N,  
537 Cristofari G, Lambrechts L, Vignuzzi M, Saleh MC. 2016. Virus-derived DNA drives  
538 mosquito vector tolerance to arboviral infection. *Nat Commun* 7:1–10.

- 539 26. Han Y, Wu Q, Ding SW. 2018. Templating Antiviral RNAi in Insects. *Cell Host Microbe*  
540 23(3):290-292.
- 541 27. Bell-Sakyi L, Kohl A, Bente DA, Fazakerley JK. 2012. Tick cell lines for study of Crimean-  
542 Congo hemorrhagic fever virus and other arboviruses. *Vector Borne Zoonotic Dis* 12:769–  
543 781.
- 544 28. Logan TM, Linthicum KJ, Bailey CL, Watts DM, Dohm DJ, Moulton JR. 1990. Replication  
545 of Crimean-Congo Hemorrhagic Fever Virus in Four Species of Ixodid Ticks (Acari)  
546 Infected Experimentally. *J Med Entomol* 27:537–542.
- 547 29. Honig JE, Osborne JC, Nichol ST. 2004. The high genetic variation of viruses of the genus  
548 Nairovirus reflects the diversity of their predominant tick hosts. *Virology* 318:10–16.
- 549 30. Růžek D, Bell-Sakyi L, Kopecký J, Grubhoffer L. 2008. Growth of tick-borne encephalitis  
550 virus (European subtype) in cell lines from vector and non-vector ticks. *Virus Res* 137:142–  
551 146.
- 552 31. Kholodilov IS, Litov AG, Klimentov AS, Belova OA, Polienko AE, Nikitin NA, Shchetinin  
553 AM, Ivannikova AY, Bell-Sakyi L, Yakovlev AS, Bugmyrin S V., Bespyatova LA, Gmyl L  
554 V., Luchinina S V., Gmyl AP, Gushchin VA, Karganova GG. 2020. Isolation and  
555 Characterisation of Alongshan Virus in Russia. *Viruses* 12:362.
- 556 32. Belova OA, Litov AG, Kholodilov IS, Kozlovskaya LI, Bell-Sakyi L, Romanova LI,  
557 Karganova GG. 2017. Properties of the tick-borne encephalitis virus population during  
558 persistent infection of ixodid ticks and tick cell lines. *Ticks Tick Borne Dis* 8:895–906.
- 559 33. Bell-Sakyi L, Attoui H. 2016. Article Commentary: Virus Discovery Using Tick Cell Lines.  
560 *Evol Bioinforma* 12s2:EBO.S39675.
- 561 34. Nag DK, Brecher M, Kramer LD. 2016. DNA forms of arboviral RNA genomes are  
562 generated following infection in mosquito cell cultures. *Virology* 498:164–171.
- 563 35. Olson KE, Bonizzoni M. 2017. Nonretroviral integrated RNA viruses in arthropod vectors:  
564 an occasional event or something more? *Curr Opin Insect Sci* 22:45-53.

- 565 36. Poirier EZ, Goic B, Tomé-Poderti L, Frangeul L, Boussier J, Gausson V, Blanc H, Vallet T,  
566 Loyd H, Levi LI, Lanciano S, Baron C, Merklings SH, Lambrechts L, Mirouze M, Carpenter  
567 S, Vignuzzi M, Saleh MC. 2018. Dicer-2-Dependent Generation of Viral DNA from  
568 Defective Genomes of RNA Viruses Modulates Antiviral Immunity in Insects. *Cell Host*  
569 *Microbe* 23:353-365.e8.
- 570 37. Houé V, Gabiane G, Dauga C, Suez M, Madec Y, Mousson L, Marconcini M, Yen PS, de  
571 Lamballerie X, Bonizzoni M, Failloux AB. 2019. Evolution and biological significance of  
572 flaviviral elements in the genome of the arboviral vector *Aedes albopictus*. *Emerg Microbes*  
573 *Infect* 8:1265–1279.
- 574 38. Houé V, Bonizzoni M, Failloux AB. 2019. Endogenous non-retroviral elements in genomes  
575 of *Aedes* mosquitoes and vector competence. *Emerg Microbes Infect* 8(1):542-555.
- 576 39. Forth JH, Forth LF, Lycett S, Bell-Sakyi L, Keil GM, Blome S, Calvignac-Spencer S,  
577 Wissgott A, Krause J, Höper D, Kampen H, Beer M. 2020. Identification of African swine  
578 fever virus-like elements in the soft tick genome provides insights into the virus' evolution.  
579 *BMC Biol* 18(1):136.
- 580 40. Russo AG, Kelly AG, Enosi Tuipulotu D, Tanaka MM, White PA. 2019. Novel insights into  
581 endogenous RNA viral elements in *Ixodes scapularis* and other arbovirus vector genomes.  
582 *Virus Evol* 5(1):vez010.
- 583 41. Nag DK, Kramer LD. 2017. Patchy DNA forms of the Zika virus RNA genome are generated  
584 following infection in mosquito cell cultures and in mosquitoes. *J Gen Virol* 98:2731–2737.
- 585 42. Andersson I, Karlberg H, Mousavi-Jazi M, Martínez-Sobrido L, Weber F, Mirazimi A. 2008.  
586 Crimean-Congo hemorrhagic fever virus delays activation of the innate immune response. *J*  
587 *Med Virol* 80:1397–1404.
- 588 43. Calistri A, Munegato D, Toffoletto M, Celestino M, Franchin E, Comin A, Sartori E, Salata  
589 C, Parolin C, Palù G. 2015. Functional Interaction Between the ESCRT-I Component  
590 TSG101 and the HSV-1 Tegument Ubiquitin Specific Protease. *J Cell Physiol* 230:1794–

591 1806.

592 44. Salata C, Monteil V, Leijon M, Bell-Sakyi L, Mirazimi A. 2020. Identification and validation  
593 of internal reference genes for real-time quantitative polymerase chain reaction-based studies  
594 in *Hyalomma anatolicum* ticks. *Ticks Tick Borne Dis* 14(11):e0008863.

595

596

## 597 **FIGURE LEGENDS**

598 **Figure 1. Hazara virus (HAZV) productively infects *Hyalomma anatolicum* tick cells without**  
599 **cytopathic effects.** (A and B) HAE/CVTVM8 and HAE/CTVM9 cells were infected at MOI 0.1 or  
600 MOI 1.0. At the indicated time points: (A) infectious viral particles in the supernatant were titrated  
601 in Vero cells, error bars = S.D.; (B) the relative increase of viral RNA in the infected cells was  
602 evaluated by qRT-PCR. Data are the results of a representative experiment. (C) Tick cell lines and  
603 human SW13 cells were infected with HAZV at MOI 0.1 and 1.0 and cell metabolism was  
604 evaluated using the MTT assay at the indicated time points. Data (mean  $\pm$  SD, N = 3 independent  
605 experiments) are percentages of optical density of infected cells with respect to that of uninfected  
606 cells set as 100%.

607

608 **Figure 2. Hazara virus (HAZV) infects *Hyalomma anatolicum* tick cells and does not affect cell**  
609 **viability.** HAE/CTVM8 cells were infected with HAZV at MOI 0.1 and (A) infected and mock-  
610 infected cells were monitored by N protein immunostaining at 6 (6d) and 15 (15d) days post  
611 infection (p.i.) and at > 1 year of culture (persistently infected) while (B) the number of live cells in  
612 infected and mock-infected control cultures were determined every day up to day 9 p.i. by trypan  
613 blue exclusion (three independent experiments) and (C) long term viral progeny release by HAZV-  
614 infected HAE/CTVM8 cells was determined by titration in Vero cells. (A) and (C) are  
615 representative of the establishment of one persistently-infected cell lines.

616



617 **Figure 3. Detection of vDNAs in *Hyalomma anatolicum* tick cells infected with Hazara virus**  
618 **(HAZV) at MOI 0.1 and 1.** (A) Schematic representation of nine pairs of primers designed on the  
619 genomic S segment of HAZV, used for the detection of vDNAs; (B) Example of vDNAs detected  
620 using the nine primer pairs at 1 (upper panel), 7 (middle panel) and 15 (lower panel) days p.i. in  
621 HAZV-infected HAE/CTVM8 and HAE/CTVM9 cells; (C) Frequency of vDNA production in the  
622 same tick cells. Data (mean  $\pm$  SD, N = 3 independent experiments) are percentages of vDNAs with  
623 respect to the maximum number of detectable amplicons (n=9), set as 100%, for each sample.

624

625 **Figure 4. Effect of ribavirin treatment on Hazara virus (HAZV) replication in persistently-**  
626 **infected *Hyalomma anatolicum* tick cells.** HAE/CTVM8 cells were treated with 100 mM ribavirin  
627 and viral replication was evaluated: (A) at different time points by viral titration; (B) at 72 h post  
628 treatment by qRT-PCR. Data are mean  $\pm$  SD of three independent experiments. \*\*\*\* p<0.0001. (C)  
629 Furthermore, production of vDNAs was suppressed by the ribavirin treatment (Lines 1-9: PCR  
630 specific for vDNAs, line 10: negative control, line 11: positive tick DNA extraction control).

631

632 **Figure 5. A cellular reverse transcriptase (RT) activity is involved in vDNA synthesis in**  
633 ***Hyalomma anatolicum* tick cells infected with Hazara virus (HAZV).** (A) Detection of RT  
634 activity in uninfected HAE/CTVM8 cells and HAE/CTVM8 cells persistently infected with HAZV  
635 (HAE/CTVM8+) using Mg<sup>2+</sup> or Mn<sup>2+</sup> as enzyme cofactor. Data are mean  $\pm$  SD of three  
636 independent experiments. (B) Schedule of azidothymine triphosphate (AZT) treatment of  
637 HAE/CTVM8 cells before (pre) or simultaneously with (post) HAZV infection. (C) Effect of AZT  
638 treatment of HAZV-infected HAE/CTVM8 cells on vDNA synthesis at 7 days p.i. Data (mean  $\pm$  SD,  
639 N = 3 independent experiments) are percentages of vDNAs detected in AZT-treated cells with  
640 respect to the vDNAs detected in the untreated cells, set as 100%.

641


642 **Figure 6. Azidothymine triphosphate (AZT) treatment of *Hyalomma anatolicum***  
643 **HAE/CTVM8 cells persistently infected with Hazara virus (HAZV) induces an increase in**  
644 **viral replication and decrease in cell metabolism.** Cells were treated with 5 mM AZT and  
645 incubated for 72 h. Then (A) the viral progeny was quantified by virus titration; (B) the presence of  
646 vDNAs was evaluated by PCR and, (C) the yield of the intracellular viral RNA was quantified by  
647 qRT-PCR. Data are mean  $\pm$  SD of three independent experiments. \*\*\*\* p<0.0001. The  
648 nucleoprotein of HAZV was (D) detected by immunostaining and (E) quantified by western blot to  
649 be 1.5 x grater in persistently-infected HAE/CTVM8 cells treated with 5 mM AZT compared to  
650 untreated cells. PI = persistently-infected cells; C- = uninfected control cells.

651


652 **Figure 7. Treatment of *Hyalomma anatolicum* HAE/CTVM8 cells with azidothymine**  
653 **triphosphate (AZT) induces death in persistently-infected cells.** (A) Tick cells persistently  
654 infected with Hazara virus were mock-treated or treated with 5 mM AZT, then cell metabolism was  
655 measured using the MTT assay at 72 h post infection (p.i.). (B) Uninfected (HAE/CTVM8) and  
656 persistently-infected (HAE/CTVM8 PI) tick cells were treated with 5 mM AZT, then cell viability  
657 was determined by trypan blue dye exclusion test at 72 h p.i.. Data are mean  $\pm$  SD of three  
658 independent experiments. \*\*\*\* p<0.0001.

659


660 **Figure 8. Detection of vDNAs in *Hyalomma anatolicum* HAE/CTVM8 cells infected with**  
661 **Crimean-Congo hemorrhagic fever virus (CCHFV).** HAE/CTVM8 cells were infected with  
662 CCHFV at MOI 0.1. Three (left panel) and seven (right panel) days after infection, total DNA was  
663 extracted and vDNAs were detected by PCR. Lines 1-11: PCR specific for vDNAs, line 12:  
664 negative control, line 13: positive tick DNA extraction control.

**A**

● HAE/CTVM8 MOI 0.1  
 ■ HAE/CTVM8 MOI 1


**B**

▲ HAE/CTVM9 MOI 0.1  
 ▼ HAE/CTVM9 MOI 1


**C**

◆ SW13 MOI 0.1  
 ● SW13 MOI 1


A




B




C





A



C




B







A




B




C




A




B




C



D




E







A



B



A



B

